RU94038427A - Peptides, conjugates, pharmaceutical compositions, treatment methods, identification method - Google Patents

Peptides, conjugates, pharmaceutical compositions, treatment methods, identification method

Info

Publication number
RU94038427A
RU94038427A RU94038427/14A RU94038427A RU94038427A RU 94038427 A RU94038427 A RU 94038427A RU 94038427/14 A RU94038427/14 A RU 94038427/14A RU 94038427 A RU94038427 A RU 94038427A RU 94038427 A RU94038427 A RU 94038427A
Authority
RU
Russia
Prior art keywords
peptides
hbv
pharmaceutical compositions
treatment
antigens
Prior art date
Application number
RU94038427/14A
Other languages
Russian (ru)
Inventor
А.Вителло Мариа
Us]
В.Чеснат Роберт
Original Assignee
Сайтел Корпорейшн (US)
Сайтел Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайтел Корпорейшн (US), Сайтел Корпорейшн filed Critical Сайтел Корпорейшн (US)
Publication of RU94038427A publication Critical patent/RU94038427A/en

Links

Abstract

FIELD: organic chemistry, peptides. SUBSTANCE: peptides stimulating cytotoxic T-lymphocytes induce HLA-limited reactions to hepatitis B virus antigens. Peptides obtained from CTL-epitopic sites both of HBV-surface and nucleocapside antigens are useful for treatment and prevention HBV infection involving treatment of chronically infected HBV carriers. Peptides can be as vaccines and pharmaceutical compositions, for example, lipid-containing compositions to enhance HLA-limited CTL reactions. Peptides are useful also for diagnostic procedures, for prediction of chronic infection form tendency development in HBV-infected persons. EFFECT: enhanced effectiveness of peptides proposed.

Claims (1)

Пептиды, стимулирующие цитотоксические Т-лимфоциты, индуцируют HLA-ограниченные реакции на антигены вируса гепатита В. Пептиды, полученные из CTL эпитопных участков как HBV поверхности, так и нуклеокапсидных антигенов, особенно пригодны для лечения и предотвращения HBV инфекции, включая лечение хронически инфицированных носителей HBV. Пептиды могут быть в виде вакцин и фармацевтических композиций, например, липидсодержащих композиций для усиления HLA-ограниченных CTL реакций. Пептиды пригодны также для таких диагностических способов, как предсказание того, кто из HBV-инфицированных индивидуумов имеет склонность к развитию у него хронической формы инфекции.Peptides that stimulate cytotoxic T lymphocytes induce HLA-limited responses to hepatitis B antigens. Peptides derived from CTL epitope sites of both HBV surface and nucleocapsid antigens are particularly useful in the treatment and prevention of HBV infection, including the treatment of chronically infected HBV carriers . The peptides can be in the form of vaccines and pharmaceutical compositions, for example, lipid-containing compositions to enhance HLA-limited CTL reactions. The peptides are also suitable for diagnostic methods such as predicting which HBV-infected individuals are prone to develop a chronic form of infection.
RU94038427/14A 1991-08-26 1992-08-26 Peptides, conjugates, pharmaceutical compositions, treatment methods, identification method RU94038427A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US827682 1992-01-29
US874491 1992-04-27
US749568 1996-11-15

Publications (1)

Publication Number Publication Date
RU94038427A true RU94038427A (en) 1996-10-20

Family

ID=25014281

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94038427/14A RU94038427A (en) 1991-08-26 1992-08-26 Peptides, conjugates, pharmaceutical compositions, treatment methods, identification method

Country Status (2)

Country Link
RU (1) RU94038427A (en)
ZA (1) ZA926441B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2469044C2 (en) * 2006-10-17 2012-12-10 Онкотерапи Сайенс, Инк. Peptide vaccines for cancer expressing mphosph1 or depdc1 polypeptides
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
US10676508B2 (en) 2015-08-12 2020-06-09 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2469044C2 (en) * 2006-10-17 2012-12-10 Онкотерапи Сайенс, Инк. Peptide vaccines for cancer expressing mphosph1 or depdc1 polypeptides
US8552146B2 (en) 2006-10-17 2013-10-08 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US8557955B2 (en) 2006-10-17 2013-10-15 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US8653234B2 (en) 2006-10-17 2014-02-18 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US9017688B2 (en) 2006-10-17 2015-04-28 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US9545437B2 (en) 2006-10-17 2017-01-17 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
US10676508B2 (en) 2015-08-12 2020-06-09 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
US11673915B2 (en) 2015-08-12 2023-06-13 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same

Also Published As

Publication number Publication date
ZA926441B (en) 1993-06-07

Similar Documents

Publication Publication Date Title
EP1018344A3 (en) HLA-restricted hepatitis B virus CTL epitopes
CN1072963C (en) Vaccine compositions
ATE277633T1 (en) PREPARATIONS AND METHODS FOR TRIGGERING CTL IMMUNITY
EP0726758A4 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
DE69233607D1 (en) Peptides that induce the cytotoxic T lymphocyte response to hepatitis B virus
ES2176232T3 (en) ADEQUATE VACCINE TO BE USED IN THE PREVENTION AND TREATMENT OF INFECTION WITH HELICOBACTER.
EP1375511A3 (en) Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
RU94040856A (en) Vaccine for oral administration
RU94038427A (en) Peptides, conjugates, pharmaceutical compositions, treatment methods, identification method
ATE285791T1 (en) VACCINE CONTAINING ACEMANNAN AS AN ADJUVANT
DE3854857T2 (en) PREVENTION AND TREATMENT OF RETROVIRUS DISEASE
ATE111485T1 (en) PEPTIDE TREATMENT OF PERSISTENT INFECTIOUS DISEASES.
CN102085366B (en) Compound vaccine adjuvant
Hayashi et al. Evaluating the immune responses stimulated by CpG oligodeoxynucleotides
DK0542895T3 (en) Cross-reactive influenza A immunization
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
Semenenko et al. Enhancement of the immune response to hepatitis B surface antigen by methyl inosine monophosphate
RU98105627A (en) VACCINES
CN1882359A (en) Pharmaceutical compositions for therapeutic use
Chuikova et al. The results of research of reactogenity and immunologic efficacy of hepatitis A and B with purified concentrated adsorbed liquid" HEP-A+ B-in-VAC" vaccine
BE837603A (en) INFLUENZA VACCINE CONTAINING PURIFIED NEURAMINIDASE AS AN ANTIGEN AND PROCESS FOR ADMINISTERING IT